The daily dose for patients with moderate or severe renal insufficiency as well as in hemodialysis – 0.2 mg. If necessary and if tolerated daily dose may masterone be increased to 0.4 mg. The most common side effects in patients receiving moxonidine: dry mouth, headache, dizziness, fatigue and drowsiness. These symptoms often diminish after the first few weeks of therapy.
There have been reports of several cases of non-fatal overdose when simultaneously used doses up to 19.6 mg.
Symptoms: headache, sedation, drowsiness, marked reduction in blood pressure, dizziness, fatigue, asthenia, bradycardia, dry mouth, vomiting, and pain in the epigastric region. Potentially also possible transient increase in blood pressure, tachycardia, hyperglycemia.
specific antidote does not exist. In case of reduction of blood pressure is recommended to restore the circulating blood volume due to fluid administration and administration of dopamine.
Bradycardia can be stopped by atropine.
Alpha-adrenoceptor antagonists can reduce or eliminate the paradoxical hypertensive effects of an overdose of moxonidine.
Interaction with other drugs
moxonidine may be administered masterone with thiazide diuretics, blockers “slow” calcium channel blockers and other antihypertensives. The combined use of moxonidine with these and other antihypertensive agents results in additive effects.
In the appointment of moxonidine with hydrochlorothiazide, glibenclamide or digoxin pharmacokinetic interactions were found.
Tricyclic antidepressants may decrease the effectiveness of antihypertensive drugs central action, and therefore it is not recommended taking them together with moxonidine.
Moxonidine is able to moderately improve cognitive impairment in patients receiving lorazepam.
Appointment Moxonidine together with benzodiazepines may be accompanied by increased sedative effect of the latter.
In appointing Moxonidine together with moclobemide pharmacodynamic interaction is absent,
If necessary, cancel both received beta-blockers first cancel beta-blockers, and only a few days.
During treatment requires regular monitoring of blood pressure, heart rate . To stop receiving the drug “Fiziotenz” should be gradual.
Effects on ability to drive the car and to the machines and management mechanisms
Studies of the effect of the drug on the ability to drive and other mechanisms have not been conducted.
There are reports of drowsiness and dizziness masterone during treatment with moxonidine. This should be considered when performing the above operations.